Turkey Company Roundup: First Biosimilar, Fraud Case Decision
This article was originally published in PharmAsia News
Arven Ilac is to launch Turkey’s first locally produced biosimilar, while a court has acquitted ex-Abdi Ibrahim employees of faud charges. Meanwhile, the Competition Authority has granted initial local approval for Sanofi and Boehringer Ingelheim’s global business swap, and a local hepatitis B vaccine is developed.
You may also be interested in...
Turkey’s efforts to control rising rates of COVID-19 are compromising the ability of hospitals to pay their debts to medtech and pharmaceutical companies. The government has devised a payments plan, but there is catch.
The Turkish medtech industry’s ongoing hospital payments problems appeared likely to come back onto the government’s agenda, with the national economy recovering somewhat in late 2019. But COVID-19 dashed those hopes.
Growth prospects for Turkey’s medical technology market are significant, but local companies have complained about public policies that are harmful to business and about the ongoing crisis in the hospital system. Now, international medtechs are starting to react, with some downscaling local operations and portfolios. Association of Research Based Medical Technologies Manufacturers president Umut Gokalp laid out the problems being faced by industry, and what action he thinks the government should take.